Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34700 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Naoya Kemmotsu und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Astellas Foundation for Research on Metabolic Disorders, Inamori Foundation, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Intracranial metastases are common in nonsmall‐cell lung cancer (NSCLC) patients, whose prognosis is very poor. In addition, intracranial progression is common during systemic treatments due to the inability to penetrate central nervous system (CNS) barriers, whereas the intracranial effects of cancer immunotherapies remain unclear. We analyzed clinical data to evaluate the frequency of intracranial progression in advanced NSCLC patients treated with PD‐1 blockade therapies compared with those treated without PD‐1 blockade therapies, and found that the frequency of intracranial progression in advanced NSCLC patients treated with PD‐1 blockade therapies was significantly lower than that in patients treated with cytotoxic chemotherapies. In murine models, intracranial rechallenged tumors after initial rejection by PD‐1 blockade were suppressed. Accordingly, long‐lived memory precursor effector T cells and antigen‐specific T cells were increased by PD‐1 blockade in intracranial lesions. However, intracranial rechallenged different tumors are not suppressed. Our results indicate that cancer immunotherapies can prevent intracranial progression, maintaining long‐term effects intracranially as well as systemically. If intracranial recurrence occurs during the treatment with PD‐1 blockade therapies, aggressive local therapies could be worthwhile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Respiratory Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan.
- Neutron Therapy Research Center, Okayama University, Okayama, Japan.
- Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
ORCID-Profile: Yosuke Togashi
Förderung
- Astellas Foundation for Research on Metabolic Disorders
- Inamori Foundation
- Japan Agency for Medical Research and Development
- Japan Science and Technology Agency
- Japan Society for the Promotion of Science
- Kato Memorial Bioscience Foundation
- MSD Life Science Foundation, Public Interest Incorporated Foundation
- Naito Foundation
Zitieren
APA
Kemmotsu, N., Ninomiya, K., Kunimasa, K., Ishino, T., Nagasaki, J., Otani, Y., Michiue, H., Ichihara, E., Ohashi, K., Inoue, T., Tamiya, M., Sakai, K., Ueda, Y., Dansako, H., Nishio, K., Kiura, K., Date, I., & Togashi, Y. (2024). Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies. International Journal of Cancer. https://doi.org/10.1002/ijc.34700
Vancouver
Kemmotsu N, Ninomiya K, Kunimasa K, Ishino T, Nagasaki J, Otani Y, et al. Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies. International Journal of Cancer. 2024. doi:10.1002/ijc.34700
BibTeX
@article{Kemmotsu2024,
author = {Kemmotsu, Naoya and Ninomiya, Kiichiro and Kunimasa, Kei and Ishino, Takamasa and Nagasaki, Joji and Otani, Yoshihiro and Michiue, Hiroyuki and Ichihara, Eiki and Ohashi, Kadoaki and Inoue, Takako and Tamiya, Motohiro and Sakai, Kazuko and Ueda, Youki and Dansako, Hiromichi and Nishio, Kazuto and Kiura, Katsuyuki and Date, Isao and Togashi, Yosuke},
title = {Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34700}
}
EUVIMED